WillItSurvive
Pharma and healthcare groups · India

Narayana Health

narayanahealth.org ↗

Indian hospital chain running low-cost cardiac and multi-specialty care across India, Cayman, and now UK.

Defensible for now
Assessed 26 July 2026 · Evidence as of 26 July 2026
Real protection, with named pressure against it.
On the recordSince 26 July 2026 · Checkable from Q2 FY27, around Nov 2026 · Every call on the record Checkpoint: Next quarterly results showing UK Practice Plus margin trend and net debt/EBITDA level
The call

Narayana Health's hospital business faces no AI predator, but its UK expansion has added debt and squeezed margins that need to recover.

Narayana Health runs hospitals across India and now the UK, making money by treating patients cheaply and well. It is hard to replace because it owns real buildings, has trained surgeons, and operates at lower cost than competitors like Apollo Hospitals, but copying that model takes years and real capital. The problem right now is that buying a UK hospital company in late 2025 almost doubled what they owe banks and shrank their profit margin, so the next year or two will show whether that UK business can earn enough money to justify the debt, or whether it was a mistake that stays expensive.

Why
01
AI pressure: None apparent. AI helps read scans and manage records here, it does not replace surgeons, beds, or licensed hospitals. Could AI do the core job? Unlikely.
02
Bigger players: Apollo Hospitals. Apollo is bigger and expanding fast in India, but hospital licenses and surgeon teams take years to copy, not quarters. Could a giant copy it? No, they are blocked.
03
What protects it. Licensed hospital beds, surgeon relationships, and a low-cost surgery model that's hard to replicate fast, plus recurring local patient flow.
What would change this call
Practice Plus (UK) operating margin over next 2 to 3 quarterly reports. Shows whether the UK acquisition is diluting profitability or integrating successfully.
Net debt to EBITDA ratio in FY27 filings versus current elevated level. Shows whether the company is deleveraging or debt is becoming a strain.
Manipal Health Enterprises IPO pricing and subscription outcome. Shows whether investor capital is rotating toward a rival hospital chain.
Key numbers
  • FY26 revenue up 44% YoY to ₹78,960 million (2026-03-31)
  • Blended EBITDA margin fell from 25.0% to 21.7% (2026-03-31)
  • UK acquisition cost about £188.78 million, closed Nov 2025 (2025-11-01)
Named risks
  • UK Practice Plus integration drags blended EBITDA margin, with UK operating margin near 9.8% versus India's 23-25%. Severity: high
  • Net borrowings roughly doubled to fund UK deal plus India capex, prompting a ₹1,500 crore debt raise sought at FY26 AGM. Severity: high
  • Manipal Health's anticipated IPO could add a larger, well-capitalized listed rival and compress sector valuation multiples. Severity: medium
  • Regulatory/compliance friction, evidenced by a ₹4,000 NSE fine for a filing delay in May 2026. Severity: low
Rivals, as read in July 2026
RivalDirectionEvidence
Apollo HospitalscontestingIndia's largest hospital chain by revenue/beds (~73-76 hospitals), as of Jan 2026
Manipal Health Enterpriseslosing toManipal has ~13,037 beds vs Narayana's ~5,900 and is pursuing an IPO as of July 2026
Ramsay Health CarecontestingCited by Narayana management as UK comparator with 60-70% NHS revenue mix, Nov 2025
Questions people ask
Is Narayana Health profitable in 2026?
Yes. Narayana Health reported FY26 (ended March 31, 2026) consolidated net profit of ₹8,104.59 million on revenue of ₹78,960.35 million, up 44% year over year, though blended EBITDA margin fell to 21.7% from 25.0% in FY25 due to the lower-margin UK acquisition.
Could AI replace Narayana Health's hospitals?
No. Surgery, transplants and ICU critical care cannot be automated away. Narayana instead deploys AI as a tool, including predictive ICU algorithms and an AI-enabled screening centre (Narayana Aarogyam, launched April 2025), while its moat rests on licensed beds, surgeon networks and NHS contracts.
Who is Narayana Health's biggest competitor?
Apollo Hospitals is India's largest hospital chain by revenue and beds (~73-76 hospitals) and the top incumbent Narayana competes against; unlisted Manipal Health Enterprises, with ~13,037 beds versus Narayana's ~5,900, is pursuing an IPO as of July 2026 and looms as a rising rival.
Who owns Narayana Health?
Narayana Health is majority owned by the Shetty family (Promoter Group), holding approximately 63.3% as of February 2026, with foreign institutional investors around 9.4-11.1% and domestic institutional investors around 9.2-9.4%; it has traded on NSE and BSE since January 6, 2016.
Why did Narayana Health's profit margin drop in 2026?
Narayana Health's blended EBITDA margin fell from 25.0% in FY25 to 21.7% in FY26 mainly because its newly acquired UK operations (Practice Plus Group, consolidated from November 2025) run at roughly 9.8% operating margin, far below India's 23-25%.
What is Narayana Health's UK expansion?
In November 2025, Narayana Health closed its £188.78 million (~₹2,100-2,200 crore) acquisition of Practice Plus Group Hospitals, the UK's 5th-largest private hospital chain and 4th-largest NHS provider, operating 12 hospitals with about 93% NHS-funded revenue and £250 million FY25 turnover.
Timeline
  • 2026-07-24FY26 annual report filed: consolidated revenue ₹78,960.35M, up 44% YoY, EBITDA margin 21.7%
  • 2026-05-20Narayana Institute of Cardiac Sciences becomes India's first HIMSS AMAM Stage 6 hospital
  • 2026-05-18Supreme Court of India quashes criminal proceedings over Kolkata hospital billing dispute
  • 2026-05-01NSE fines Narayana Health ₹4,000 for a filing delay
  • 2026-02-13NSE investor presentation shows Promoter Group holding ~63.3% ownership
  • 2025-11-01Narayana Health closes acquisition of UK's Practice Plus Group Hospitals for £188.78 million
  • 2025-10-29Partnership announced with Biostate AI's Bayosthiti AI to build India-specific cardiac AI dataset
  • 2025-05-25Company announces ₹3,000 crore domestic capex plan to add ~2,000 beds by FY28/29
  • 2025-04-07Narayana Aarogyam AI-enabled preventive screening centre launched in Bengaluru
  • 2016-01-06Narayana Health lists on NSE and BSE at a market valuation over $1 billion
Revision history
26 July 2026
First assessed. Defensible for now. The text above is fixed as of this date and is not edited afterwards.
In the same band
ZoetisBoston ScientificBecton Dickinson
More in Pharma and healthcare groups →
Sources